8th EUROPEAN SCHOOL OF DERMATO-ONCOLOGY
UPDATE ON CUTANEOUS ONCOLOGY (ESDO)
JANUARY 16th-18th, 2020
ABBA HOTEL BERLIN, GERMANY

www.dermato-oncology2020.org
# Content

<table>
<thead>
<tr>
<th>European Association of Dermato-Oncology (EADO)</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target Audience</td>
<td>2</td>
</tr>
<tr>
<td>Educational Objectives</td>
<td>2</td>
</tr>
<tr>
<td>Course Organization</td>
<td>3</td>
</tr>
<tr>
<td>Program Overview</td>
<td>4</td>
</tr>
<tr>
<td>Program</td>
<td>6</td>
</tr>
<tr>
<td>Thursday, January 16\textsuperscript{th}, 2020</td>
<td>6</td>
</tr>
<tr>
<td>Friday, January 17\textsuperscript{th}, 2020</td>
<td>7</td>
</tr>
<tr>
<td><em>Non-Melanoma Skin Cancer Day</em></td>
<td></td>
</tr>
<tr>
<td>Saturday, January 18\textsuperscript{th}, 2020</td>
<td>10</td>
</tr>
<tr>
<td>Course Faculty</td>
<td>11</td>
</tr>
<tr>
<td>General Information</td>
<td>15</td>
</tr>
<tr>
<td>Registration Form</td>
<td>17</td>
</tr>
</tbody>
</table>

www.dermato-oncology2020.org
European Association of Dermato-Oncology (EADO)

The EADO is a non-profit organization funded in 1999 to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. EADO has organized many successful meetings and the upcoming ones are visible on the website (www.eado.org).

The EADO initiates for the eighth time a course dedicated to fundamentals in skin cancer targeted to specialists and residents in the final phase of their resident program. They will benefit a comprehensive and updated course to improve their decision-making process for the management of all types and stages of skin cancer, from diagnosis, primary treatment and adjuvant treatment, to the management of locoregional disease and distant metastatic disease.

Target Audience

This 2,5-day educational course targets doctors who are actively involved in the treatment of skin cancer. Dermatologists or other specialists who have completed specialist training, or residents in the final year of their training program, are likely to gain the most from this course.

Educational Objectives

The principal aim of the course is to provide a comprehensive and detailed understanding of the decision-making process for the management of all types and stages of skin cancer. This will include diagnosis and primary treatment, management of locoregional disease and distant metastatic disease, and adjuvant treatment. This is particularly relevant given the rapid progress in our understanding of melanoma and non-melanoma skin cancer, and the development of new treatments. In particular delegates will acquire the following knowledge:

1. Strategies for diagnosis of melanoma, Merkel cell and non-melanoma skin cancer including dermoscopy and confocal laser microscopy.
2. The indications, risks and benefits and strategies for mole screening.
3. Diagnosis of skin cancer: how to break bad news.
5. The present AJCC staging systems and how to stage melanoma, Merkel cell and cutaneous squamous cell carcinoma, and other non-melanoma skin cancers.
6. The value of imaging and biomarkers for the detection of metastases and disease staging.
8. New systemic treatments for stage IV melanoma: targeted agents and immunotherapeutics.
10. New systemic treatments for advanced Merkel cell and squamous cell carcinoma.
11. The characteristics of mucosal and uveal melanomas and their treatment options.
12. Options for topical treatment of epithelial skin cancers.
13. The current classification of cutaneous lymphoma, staging and treatment options for different subtypes of cutaneous lymphoma.
15. The indications and strategies for supportive treatments including best supportive care.

Course Organization

The course consists of plenary sessions and interactive outbreak sessions. Plenary sessions will comprise clear structured and up-to-date presentations followed by audience discussion. Voting devices will be used to respond to multiple choice questions. These questions may precede the presentation of the structured knowledge or may be presented at the end in order to test the level of knowledge the audience has gained.

The main part of the course consists of 8 interactive sessions, each with no more than 30 attendants. Every participant takes part in each of these sessions which mainly comprise case-based discussion. These will be used to illustrate treatment pathways, how risk and benefit are assessed, and how management decisions are made.

We look forward to welcoming you in Berlin in January 2020!

Ana-Maria Forsea, MD    Claus Garbe, MD    Axel Hauschild, MD    Judit Oláh, MD

Course Directors
Program Overview

A commercial exhibition will be held on all days close to the meeting rooms.

<table>
<thead>
<tr>
<th>Time</th>
<th>08:00</th>
<th>09:00</th>
<th>10:00</th>
<th>11:00</th>
<th>12:00</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thursday</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>January 16th, 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group III</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Friday</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>January 17th, 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group III</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Saturday</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>January 18th, 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group III</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Lectures:**
- **Pamplona + Santander**
  - Course A+E: Pamplona
  - Course B+F: Santander
  - Course C+G: Burgos
  - Course D+H: Salamanca

**All meeting rooms are located on the ground floor.**
<table>
<thead>
<tr>
<th>Time</th>
<th>COURSE A</th>
<th>COURSE B</th>
<th>COURSE C</th>
<th>COURSE D</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>J. J. Grob</td>
<td>C. Lebbé</td>
<td>C. GARBE</td>
<td>P. NATHAN</td>
</tr>
<tr>
<td>14:00</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
<td>Break</td>
</tr>
<tr>
<td>15:00</td>
<td>COURSE A</td>
<td>COURSE B</td>
<td>COURSE C</td>
<td>COURSE D</td>
</tr>
<tr>
<td>16:00</td>
<td>J. J. Grob</td>
<td>C. Lebbé</td>
<td>C. GARBE</td>
<td>P. NATHAN</td>
</tr>
<tr>
<td>17:00</td>
<td>COURSE A</td>
<td>COURSE B</td>
<td>COURSE C</td>
<td>COURSE D</td>
</tr>
<tr>
<td>18:00</td>
<td>J. J. Grob</td>
<td>C. Lebbé</td>
<td>C. GARBE</td>
<td>P. NATHAN</td>
</tr>
</tbody>
</table>

**COURSE A**
- J. J. Grob

**COURSE B**
- C. Lebbé

**COURSE C**
- C. GARBE

**COURSE D**
- P. NATHAN
# Program

**Thursday, January 16th, 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45–14:00</td>
<td>Welcome and course introduction</td>
</tr>
<tr>
<td></td>
<td><em>Claus Garbe, Tuebingen, Germany</em></td>
</tr>
<tr>
<td>14:00–14:15</td>
<td><strong>PLENARY SESSION 1: What is new in diagnostics and treatment?</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chairpersons: Iris Zalaudek and Joseph Malvehy</em></td>
</tr>
<tr>
<td>14:40–14:55</td>
<td><strong>LECTURE 3: Update on imaging tools in skin cancers</strong></td>
</tr>
<tr>
<td></td>
<td><em>Josep Malvehy, Barcelona, Spain</em></td>
</tr>
<tr>
<td>14:20–14:35</td>
<td><strong>LECTURE 2: Computer dermoscopy: a must?</strong></td>
</tr>
<tr>
<td></td>
<td><em>Aimilios Lallas, Thessaloniki, Greece</em></td>
</tr>
<tr>
<td>14:00–14:15</td>
<td><strong>LECTURE 1: Dermoscopy of difficult lesions - beyond ABCD</strong></td>
</tr>
<tr>
<td></td>
<td><em>Iris Zalaudek, Trieste, Italy</em></td>
</tr>
<tr>
<td>15:00–15:15</td>
<td><strong>LECTURE 4: The neoadjuvant approach in skin cancer</strong></td>
</tr>
<tr>
<td></td>
<td><em>Christoph Höller, Vienna, Austria</em></td>
</tr>
<tr>
<td>15:15–15:30</td>
<td>Discussion</td>
</tr>
<tr>
<td>15:30–16:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16:00–17:00</td>
<td><strong>COURSE A: Clinical trials fundamentals- understanding trial design, data analysis, result interpretation and ethical issues</strong></td>
</tr>
<tr>
<td></td>
<td><em>Jean Jacques Grob, Marseille, France</em></td>
</tr>
<tr>
<td>16:00–17:00</td>
<td><strong>COURSE B: How to organize a skin cancer center?</strong></td>
</tr>
<tr>
<td></td>
<td><em>Celeste Lebbé, Paris, France</em></td>
</tr>
<tr>
<td>16:00–17:00</td>
<td><strong>COURSE C: Management of melanoma patients stages I-III</strong></td>
</tr>
<tr>
<td></td>
<td><em>Claus Garbe, Tuebingen, Germany</em></td>
</tr>
<tr>
<td>16:00–17:00</td>
<td><strong>COURSE D: Targeted therapy of melanoma, SCC, BCC and DFSP</strong></td>
</tr>
<tr>
<td></td>
<td><em>Paul Nathan, Northwood, United Kingdom</em></td>
</tr>
</tbody>
</table>
### Friday, January 17th, 2020

**Non-Melanoma Skin Cancer Day**

---

**PLENARY SESSION 2: Controversies in Dermatooncology**

*Chairpersons: Jean Jacques Grob and Alex Stratigos*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Place</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-08:15</td>
<td>Lecture</td>
<td>Skin cancer screening saves lifes: Yes</td>
<td>Pamplona+Santander</td>
<td>Alex Stratigos, Athens, Greece</td>
</tr>
<tr>
<td>08:15-08:30</td>
<td>Lecture</td>
<td>Skin cancer screening saves lifes: No</td>
<td>Pamplona+Santander</td>
<td>Dirk Schadendorf, Essen, Germany</td>
</tr>
<tr>
<td>08:30-08:45</td>
<td></td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:45-09:00</td>
<td>Lecture</td>
<td>Sunscreens prevent skin cancer: Yes</td>
<td>Pamplona+Santander</td>
<td>Veronique del Marmol, Brussels, Belgium</td>
</tr>
<tr>
<td>09:00-09:15</td>
<td>Lecture</td>
<td>Sunscreens prevent skin cancer: No</td>
<td>Pamplona+Santander</td>
<td>Claus Garbe, Tuebingen, Germany</td>
</tr>
<tr>
<td>09:15-09:30</td>
<td></td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**17:00-17:30** Coffee Break

**17:30-18:30**

- **COURSE B: How to organize a skin cancer center?**
  *Celeste Lebbé, Paris, France*

  **Group I**

- **COURSE C: Management of melanoma patients stages I-III**
  *Claus Garbe, Tuebingen, Germany*

  **Group II**

- **COURSE D: Targeted therapy of melanoma, SCC, BCC and DFSP**
  *Paul Nathan, Northwood, United Kingdom*

  **Group III**

- **COURSE A: Clinical trials fundamentals- understanding trial design, data analysis, result interpretation and ethical issues**
  *Jean Jacques Grob, Marseille, France*

  **Group IV**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00–11:00</td>
<td>COURSE E: <strong>Principals of follow-up in skin cancer patients</strong></td>
<td>Ana Maria Forsea, Bucharest, Romania</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group I Pamplona</td>
</tr>
<tr>
<td>10:00–11:00</td>
<td>COURSE F: <strong>Cutaneous lymphomas: diagnosis and management</strong></td>
<td>Michael Weichenthal, Kiel, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group II Santander</td>
</tr>
<tr>
<td>10:00–11:00</td>
<td>COURSE G: <strong>Surgical pearls in the treatment of keratinocyte skin cancer</strong></td>
<td>Roland Kaufmann, Frankfurt, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group III Burgos</td>
</tr>
<tr>
<td>10:00–11:00</td>
<td>COURSE H: <strong>Immune checkpoint inhibition for melanoma, MCC, SCC and BCC</strong></td>
<td>Axel Hauschild, Kiel, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group IV Salamanca</td>
</tr>
<tr>
<td>11:00–11:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>11:30–12:30</td>
<td>COURSE F: <strong>Cutaneous lymphomas: diagnosis and management</strong></td>
<td>Michael Weichenthal, Kiel, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group I Pamplona</td>
</tr>
<tr>
<td>11:30–12:30</td>
<td>COURSE G: <strong>Surgical pearls in the treatment of keratinocyte skin cancer</strong></td>
<td>Roland Kaufmann, Frankfurt, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group II Santander</td>
</tr>
<tr>
<td>11:30–12:30</td>
<td>COURSE H: <strong>Immune checkpoint inhibition for melanoma, MCC, SCC and BCC</strong></td>
<td>Axel Hauschild, Kiel, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group III Burgos</td>
</tr>
<tr>
<td>11:30–12:30</td>
<td>COURSE E: <strong>Principals of follow-up in skin cancer patients</strong></td>
<td>Ana Maria Forsea, Bucharest, Romania</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group IV Salamanca</td>
</tr>
<tr>
<td>12:30–13:00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PLENARY SESSION 3: New challenges in skin cancer treatment</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairpersons: Holger Hänßle and Ketty Peris</td>
<td></td>
</tr>
<tr>
<td>13:00–13:30</td>
<td>LECTURE 9: <strong>Artificial intelligence in skin cancer diagnosis</strong></td>
<td>Holger Hänßle, Heidelberg, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pamplona+Santander</td>
</tr>
<tr>
<td>13:30–14:00</td>
<td>LECTURE 10: <strong>What is new for actinic keratosis?</strong></td>
<td>Ketty Peris, Rome, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pamplona+Santander</td>
</tr>
<tr>
<td>14:00–15:00</td>
<td>Non-Melanoma skin cancer cases – interactive presentation to the tumor board</td>
<td>Ana Maria Forsea, Petr Arenberger, David Moreno</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>
| 15:30-16:30 | COURSE G: Surgical pearls in the treatment of keratinocyte skin cancer  
| Group I Pamplona | Roland Kaufmann, Frankfurt, Germany                                 |
| 15:30-16:30 | COURSE H: Immune checkpoint inhibition for melanoma, MCC, SCC and BCC  
| Group II Santander | Axel Hauschild, Kiel, Germany                                       |
| 15:30-16:30 | COURSE E: Principals of follow-up in skin cancer patients            
| Group III Burgos | Ana Maria Forsea, Bucharest, Romania                                |
| 15:30-16:30 | COURSE F: Cutaneous lymphomas: diagnosis and management              
| Group III Burgos | Michael Weichenthal, Kiel, Germany                                   |
| 16:30-17:00 | Coffee Break                                                        |
| 17:00-18:00 | COURSE H: Immune checkpoint inhibition for melanoma, MCC, SCC and BCC  
| Group I Pamplona | Axel Hauschild, Kiel, Germany                                       |
| 17:00-18:00 | COURSE E: Principals of follow-up in skin cancer patients            
| Group II Santander | Ana Maria Forsea, Bucharest, Romania                                |
| 17:00-18:00 | COURSE F: Cutaneous lymphomas: diagnosis and management              
| Group III Burgos | Michael Weichenthal, Kiel, Germany                                   |
| 17:00-18:00 | COURSE G: Surgical pearls in the treatment of keratinocyte skin cancer  
<p>| Group IV Salamanca | Roland Kaufmann, Frankfurt, Germany                                 |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:30</td>
<td>COURSE C: Management of melanoma patients stages I-III</td>
<td>Pamplona</td>
<td>Claus Garbe, Tuebingen, Germany</td>
</tr>
<tr>
<td>08:30-09:30</td>
<td>COURSE D: Targeted therapy of melanoma, SCC, BCC and DFSP</td>
<td>Santander</td>
<td>Paul Nathan, Northwood, United Kingdom</td>
</tr>
<tr>
<td>08:30-09:30</td>
<td>COURSE A: Clinical trials fundamentals- understanding trial design, data analysis, result interpretation and ethical issues</td>
<td>Burgos</td>
<td>Jean Jacques Grob, Marseille, France</td>
</tr>
<tr>
<td>08:30-09:30</td>
<td>COURSE B: How to organize a skin cancer center?</td>
<td>Salamanca</td>
<td>Celeste Lebbé, Paris, France</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00-11:00</td>
<td>COURSE D: Targeted therapy of melanoma, SCC, BCC and DFSP</td>
<td>Pamplona</td>
<td>Paul Nathan, Northwood, United Kingdom</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td>COURSE A: Clinical trials fundamentals- understanding trial design, data analysis, result interpretation and ethical issues</td>
<td>Santander</td>
<td>Jean Jacques Grob, Marseille, France</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td>COURSE B: How to organize a skin cancer center?</td>
<td>Burgos</td>
<td>Celeste Lebbé, Paris, France</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td>COURSE C: Management of melanoma patients stages I-III</td>
<td>Salamanca</td>
<td>Claus Garbe, Tuebingen, Germany</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>PLENARY SESSION 4: Melanoma diagnostics and follow-up</td>
<td></td>
<td>Ketty Peris</td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>LECTURE 11: Targeted therapies: management of adverse events</td>
<td>Pamplona+Santander</td>
<td>Lidija Kandolf Sekulovic, Belgrade, Serbia</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>LECTURE 12: Immune checkpoint inhibition: management of adverse events</td>
<td>Pamplona+Santander</td>
<td>Christoffer Gebhardt, Hamburg, Germany</td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>Melanoma cases - interactive presentation to the tumor board</td>
<td>Pamplona+Santander</td>
<td>Judit Oláh, Lidija Kandolf, Ricardo Vieira</td>
</tr>
</tbody>
</table>
Invited Course Faculty

A

Petr Arenberger, MD
Professor of Dermatology, Director
Department of Dermatology
Charles University
3rd School of Medicine
Srobarova 50
CZ-100 34 Prague, Czech Republic
Phone: +420-26716-3000
Email: avemedica@email.cz

D

Veronique Del Marmol, MD
Department of Clinical Chemistry
Erasme Hospital – ULB
Route de Lennik 808
1070 Brussels, Belgium

F

Ana-Maria Forsea, MD
Assistant Professor for Dermatology
Department of Dermatology
Carol Davila University of Medicine and Pharmacy Bucharest
Bulevardul Eroii Sanitari 8
050474 Bucharest, Romania
Phone: +40-21-3180462
Email: aforsea@yahoo.com

G

Claus Garbe, MD
Professor of Dermatology
Department of Dermatology
Eberhard Karls University
Liebermeister Str. 25
72076 Tuebingen, Germany
Phone: +49-7071-2987110
Email: claus.garbe@med.uni-tuebingen.de

Christoffer Gebhardt, MD
Skin Cancer Center
University Hospital Hamburg-Eppendorf
Martinistr. 52
20246 Hamburg, Germany
Phone: +49-40-741057626
Email: ch.gebhardt@uke.de

Jean Jacques Grob, MD
Professor of Dermatology
Service de Dermatology and Cancer Research
Hôpital de la Timone
264 Rue St. Pierre
13005 Marseille, France
Phone: +33-491-388591
Email: jean-jacques.grob@ap-hm.fr
**Holger Hänßle, MD**  
Heidelberg University Hospital  
Im Neuenheimer Feld 400  
69120 Heidelberg, Germany

**Axel Hauschild, MD**  
Professor of Dermatology  
Department of Dermatology  
University of Kiel  
Rosalind-Franklin-Str. 7  
24105 Kiel, Germany  
Phone: +49-431-50021131  
Email: ahauschild@dermatology.uni-kiel.de

**Christoph Höller, MD**  
Professor of Dermatology  
Department of Dermatology  
Medical University of Vienna  
Waehringer Guertel 18–20  
1090 Vienna, Austria  
Phone: +43-1-404004786  
Email: christoph.hoeller@meduniwien.ac.at

**Lidija Kandolf Sekulovic, MD**  
Professor of Dermatology  
Department of Dermatology  
Medical Faculty  
Military Medical Academy  
Crnotravska 17  
11000 Belgrade, Serbia  
Phone: +381-11-3608583  
Email: lkandolfsekulovic@gmail.com

**Roland Kaufmann, MD**  
Professor of Dermatology, Director  
Department of Dermatology  
Clinical Center J. W. Goethe University  
Theodor-Stern-Kai 7  
60590 Frankfurt/Main, Germany  
Phone: +49-69-63015311  
Email: kaufmann@em.uni-frankfurt.de

**Aimilios Lallas, MD**  
Aristotle University of Thessaloiki  
Department of Dermatology  
54124 Thessaloniki, Greece

**Celeste Lebbé, MD**  
Professor of Dermatology  
Department of Dermatology  
Hôpital Saint-Louis  
1, Avenue Claude-Vellefaux  
75010 Paris, France  
Phone: +33-142494679  
Email: celeste.lebbe@aphp.fr

**Josep Malvehy, MD**  
Director of the Melanoma Unit  
Department of Dermatology  
Hospital Clinic of Barcelona  
C/Villarroel 170  
08036 Barcelona, Spain  
Phone: +34-933638920  
Email: jmalvehy@clinic.ub.es
David Moreno-Ramirez, MD
University Hospital Virgen Macarena
Calle Dr. Fedriani, 3
41009 Seville, Spain

Paul Nathan, MD
Mount Vernon Cancer Centre
Rickmansworth Rd, Northwood
United Kingdom
Email: p.nathan@nhs.net

Judit Oláh, MD
Department of Dermatology
University of Szeged
Koranyi Fasor 6
3720 Szeged, Hungary
Phone: +36-62-545984
Email: dr.olah.judit@gmail.com

Ketty Peris, MD
Department of Dermatology
Catholic University of Rome
Largo a Gemelli, 8
00168 Rome, Italy
Phone: +39-630154227
Email: ketty.peris@rm.unicatt.it

Dirk Schadendorf, MD
University Hospital of Essen
Hufelandstr. 55
45147 Essen, Germany
Phone: +49-201-7232430
Email: dirk.schadendorf@uk-essen.de

Alexander Stratigos, MD
Department of Dermatology
University of Athens
School of Medicine
Andreas Sygros Hospital
5 Dragoumi Street
Athens 161 21, Greece
Phone: +30-210-7231731
Email: alstrat2@gmail.com

Ricardo Vieira, MD
Faculty of Medicine
University of Coimbra
Pólo I - Edifício Central
Rua Larga
3004-504 Coimbra, Portugal
Phone: +35-1-3957-00
Email: ricardo.vieira@portugalmail.pt
W

Michael Weichenthal, MD
Professor of Dermatology
Department of Dermatology
University of Kiel
Rosalind-Franklin-Str. 7
24105 Kiel, Germany
Phone: +49-431-500-21141
Email:mweichenthal@dermatology.uni-kiel.de

Z

Iris Zalaudek, MD
Head of the Dermatology Clinic
University of Trieste
Hospital Maggiore
Piazza dell’ Ospedale 1
34125 Trieste, Italy
Email: iris.zalaudek@gmail.com
Cancellation Policy
Cancellations must be received in writing by December 19, 2019. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions are possible. To substitute a registration, please send an email including the name of the original registrant and the name of the person substituting to info@medconcept.org.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

Course Organization

MedConcept Gesellschaft für medizinische Projekte mbH
Friedenstraße 58
15366 Neuenhagen b. Berlin, Germany
Phone: +49 (0)3342 42689-30
Fax: +49 (0)3342 42689-40
E-Mail: info@medconcept.org
www.medconcept.org

Course Venue
ABBA Hotel Berlin
Lietzenburger Str. 89
10719 Berlin
Germany
Phone: +49 (0)30 8871860
E-Mail: berlin@abbahoteles.com
Exhibition Opening Hours
Thursday, January 16: 13:00–18:30
Friday, January 17: 07:30–18:00
Saturday, January 18: 08:00–13:30

Fees
Registration Fee of **380 Euro (incl. VAT)** covers

- Admission to scientific sessions
- Admission to exhibition
- Bag with course documents
- Welcome reception
- Coffee breaks and lunch
- Certificate of attendance

Language and Translation
The official language of the meeting will be English. Simultaneous translation will not be provided.

Registration/Information Desk
The registration desk is situated at the ground floor of the Novotel Berlin am Tiergarten.

Opening hours
Thursday, January 16: 12:00–19:00
Friday, January 17: 07:30–18:00
Saturday, January 18: 08:00–14:00
Registration Form
8th European School of Dermato-Oncology

First Name: ___________________________  Last Name: ___________________________

Professional Title: ___________________  Degree:  MD  PhD  RN  PA-C

Gender:  Male  Female  Speciality: ___________________________

Institution: ___________________________  Address: ___________________________

City: ___________________  Zip Code: ___________________  Country: ___________________

Phone: ________________  Fax: ________________  E-Mail: ___________________________

**Fees** – Registration Fee of **380,00 Euro** (incl. VAT) covers
- Admission to scientific sessions
- Admission to exhibition
- Welcome reception
- Bag with course documents
- Coffee breaks and lunch
- Certificate of Attendance

**Payment Method**

Bank Transfer:  Registration can only be confirmed upon receipt of full payment.

Credit Card:  MasterCard  Visa  American Express

Credit Card Number: ___________________________

Expiration Date: ___________________________

Security Code CCV: ________________  (MC/Visa - 3 digits on back, AMEX - 4 digits on front)

Cardholder Name: ___________________________

Signature: ___________________________

An invoice will be send by email to the given address. If the invoice address is different from the address given above, please send an email including the name of the registrant and the full invoice address to christopher.huhn@medconcept.org.

By completing the registration form, the participant accepts the general terms and conditions as well as the cancellation policy given on the congress website at www.melanomaglobal2020.org and agrees that his/her data may be used, processed and published (e.g. within the list of participants) for organizational purposes of the event. The participant accepts that MedConcept will contact him/her by email for organizational matters (e.g. the registration confirmation and invoice) and information related to the event.

I accept until further notice that MedConcept will inform me about future events by email.

**To Register**

Mail registration form to: MedConcept GmbH, Friedenstraße 58, 15366 Neuenhagen bei Berlin, Germany
Fax registration form to: +49 (0)3342 42689-40, Register online: www.dermato-oncology2020.org
The EUROPEAN CERTIFICATION for MEDICAL TUMOR THERAPY in DERMATO-ONCOLOGY:

Register now for the 2020 Examination!

The professional competence in conducting systemic therapy for skin cancers is certified by the European Certificate for Medical Tumour Therapy in Dermato-oncology awarded by EADO in collaboration with UEMS.

The Certification is acquired upon successfully passing the EADO Examination, which will be held on Saturday 18th January 2020 during the 8th European School of Dermato-Oncology, Berlin, Germany.

The Examination is open for Dermatology specialists and final year residents with clinical experience in the systemic treatment of skin cancers.

Deadline for application: December 1st 2019

Please visit the www.eado.org website to keep informed about the latest updates and feel free to contact the EADO office at info@eado.org for any query.

EADO - European Association of Dermato-Oncology. An organization dedicated to promote, coordinate and improve clinical and laboratory research in skin cancer. A non-profit Organization registered in Switzerland, AG Flugofstrasse 54, CH-8152 Glattburg.

Please feel free to contact the Secretariat Office. Tel.: +33 (0)1 53 85 82 70, info@eado.org, www.eado.org